Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCERTAIN: Sarilumab vs Tocilizumab in RA
NCT01768572Phase 3Completed
- Sponsor
- Sanofi
- Start
- Mar 2013
- Primary completion
- Oct 2014
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial of sarilumab in rheumatoid arthritis (RA) (3 arms), sponsored by Sanofi. Primary endpoint: Treatment Emergent Adverse Events at 24 weeks. Started Mar 2013; status: completed.
02
Drugs
sarilumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01768572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01768572.